As OTC derivatives regulation moves into the realm of ‘business as usual’ for many trading counterparts in the US and EU, Australia has only taken tentative steps forward in transforming the G20 commitments into enforced regulations.
In Australia, there are opposing views within the OTC derivatives industry – on one side of the debate, some people advocate regulation as a necessary step to ensure Australia remains competitive in the global markets; likewise, there are people who believe that regulations would restrict a market that was not riddled with problems to begin with.
GreySpark Partners consultant Malavika Shekar looks at Australia’s regulatory outlook against the backdrop of local policy and market sentiment.
